Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference
via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company")
(NASDAQ, TSX: NVCN), a leader in the development of minimally
invasive transcatheter mitral valve replacement technologies, and
minimally invasive devices for the treatment of refractory angina,
today announced that its management team will be participating in
the 22nd Annual H.C. Wainwright Global Investment Conference on
September 14-16, 2020. Fred Colen, Neovasc’s President and
CEO, will present on September 15 at 3:30 pm EDT.
A link to the live webcast of Mr. Colen’s presentation will be
available online through the investor relations section of the
Neovasc website at https://www.neovasc.com/investors/.
Following the event, a replay of the presentation will be
archived on the Neovasc website for approximately 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact.
When used herein, the words "expect", "anticipate", "estimate",
"may", "will", "should", "intend," "believe", and similar
expressions, are intended to identify forward-looking
statements. Forward-looking statements may involve, but are
not limited to, expectations as to the future growth of the
Company, the expansion of its product range and the growing
cardiovascular marketplace. Forward-looking statements are based on
estimates and assumptions made by the Company in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Report on Form 20-F and in the Management's
Discussion and Analysis for the three and six months ended June 30,
2019 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These
factors should be considered carefully, and readers should not
place undue reliance on the Company's forward-looking statements.
The Company has no intention and undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Historical Stock Chart
From Dec 2020 to Jan 2021
Historical Stock Chart
From Jan 2020 to Jan 2021